Invivyd (IVVD) Cash from Financing Activities (2021 - 2025)
Invivyd posted quarterly Cash from Financing Activities of $157.2 million for Q4 2025, up 204025.97% year-on-year from N/an in Q4 2024, and up 169.54% on a QoQ basis from $58.3 million in Q3 2025.
Invivyd (IVVD) has 5 years of Cash from Financing Activities data on file, last reported at $157.2 million in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities rose 204025.97% year-over-year to $157.2 million; the trailing twelve-month figure through Dec 2025 stood at $215.6 million (up 448.24% YoY), and the FY2025 full-year result was $215.6 million, up 448.24% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at $157.2 million, up from $58.3 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $334.8 million in Q2 2021 and bottomed at -$749000.0 in Q4 2021.
- The 5-year median for Cash from Financing Activities is $141000.0 (2022), against an average of $48.4 million.
- The widest annual swing landed in 2022, when Cash from Financing Activities slumped 99.98%; it then jumped 204025.97% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at -$749000.0 in 2021, then soared by 118.83% to $141000.0 in 2022, then changed by 0.0% to $141000.0 in 2023, then tumbled by 45.39% to $77000.0 in 2024, then surged by 204025.97% to $157.2 million in 2025.
- The last three Cash from Financing Activities figures came in at $157.2 million (Q4 2025), $58.3 million (Q3 2025), and $131000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | 157.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 157.18 Mn |
| Dec 31, 2025 | 157.18 Mn |
| Sep 30, 2025 | 58.31 Mn |
| Sep 30, 2025 | 58.31 Mn |
| Jun 30, 2025 | 131,000.00 |
| Jun 30, 2025 | 131,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Jun 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 92,000.00 |
| Mar 31, 2024 | 39.10 Mn |
| Mar 31, 2024 | 39.10 Mn |
| Dec 31, 2023 | 141,000.00 |
| Dec 31, 2023 | 141,000.00 |
| Sep 30, 2023 | 92,000.00 |
| Sep 30, 2023 | 92,000.00 |
| Jun 30, 2023 | 270,000.00 |
| Jun 30, 2023 | 270,000.00 |
| Mar 31, 2023 | 542,000.00 |
| Mar 31, 2023 | 542,000.00 |
| Dec 31, 2022 | 141,000.00 |
| Dec 31, 2022 | 141,000.00 |
| Sep 30, 2022 | 246,000.00 |
| Sep 30, 2022 | 246,000.00 |
| Jun 30, 2022 | 74,000.00 |
| Jun 30, 2022 | 74,000.00 |
| Mar 31, 2022 | 45,000.00 |
| Mar 31, 2022 | 45,000.00 |
| Dec 31, 2021 | -749,000.00 |
| Dec 31, 2021 | -749,000.00 |
| Sep 30, 2021 | 328.60 Mn |
| Sep 30, 2021 | 328.60 Mn |
| Jun 30, 2021 | 334.83 Mn |
| Jun 30, 2021 | 334.83 Mn |